Abbott Laboratories Corporation

Other

Fatima Z Basha

John F DeBernardis

Robert J Altenbach

William A Carroll

Michael D Meyer

Michael D Wendt

Irene I Drizin

James F Kerwin

Biswanath De

Robert E Zelle

Thomas W Von Geldern

Diane M Yamamoto

John K Pratt

Steven Armen Boyd

Martin Winn

Kevin B Sippy

Saul H Rosenberg

Anthony K Fung

Daniel Joseph Kerkman

Karin Rosemarie Tietje

Thomas M Zydowsky

Kazumi Shiosaki

Suzanne A Lebold

Edmund L Lee

Andrew Stewart Tasker

Anthony Ralph Haight

Kent D Stewart

Michael E Kort

Zhonghua Pei

Kenton L Longenecker

Hong Yong

Richard J Perner

Andrew S Judd

David M Stout

Xiaofeng Li

Mathew M Mulhern

David J Madar

Jeffrey A Kester

Robert J Gregg

Chi-nung W Hsiao

Yvonne Connolly Martin

Kenneth P Spina

John W Kebabian

Robert W Schoenleber

Weijiang Zhang

Michael P DeNinno

Arturo Perez Medrano

Bradley J Backes

J&uuml;rgen Dinges

Stanley DiDomenico, Jr

Steven W Elmore

The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

Aminal diones as potassium channel openers

Benzoxazine &agr;-1 adrenergic compounds

The present invention relates to a compound of the formula and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and treating BPH.

Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adrenergic compounds

The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and tr

Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adenergic compounds

The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

Bicyclic substituted hexahydrobenz �e! isoindole alpha-1 adrenergic

The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an .alpha.-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic

Compounds are disclosed having the formula: ##STR1## wherein the substituents are defined herein. The compounds of the invention are angiotensin II receptor antagonists.

Angiotensin II receptor antagonists

Compounds are disclosed having the formula: ##STR1## The compounds of the invention are angiotensin II receptor antagonists.

Compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein m is 0, 1 or 2 and n is 0 or 1;

Biogentic amine uptake inhibitors

Compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein M is 0, 1 or 2 and n is 0 or 1;

Biogenic amine uptake inhibitors

The present invention includes compounds represented by the formula: ##STR1## wherein n is 0 or 1; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently selected from hydrogen, hydroxyl, amino, alkylamino, alkylsulfonylamino, loweralkyl, loweralkoxy, halo, and thioalkoxy; R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 taken together can form a methylenedioxy or ethylenedioxy bridge; R.sub.10 is independently selected from hydrogen, loweralkyl, phenyl, and substituted phenyl; R.sub.5 is loweralkyl; R.sub.9 is hydrogen or loweralkyl; R.sub.6 and R.sub.8 are hydrogen; and R.sub.7 is ##STR2## wherein m is 0, 1 or 2; X is CH.sub.2, O, S or N--CH.sub.3 ; or R.sub.7 is ##STR3## wherein s is 0, 1, or 2; Z is C or N; R.sub.11 and R.sub.12 are independently selected from hydrogen, halo, hydroxy, methoxy, thiomethoxy, amino and loweralkyl, or R.sub.11 and R.sub.12 taken together can form a methylenedioxy or ethylenedioxy bridge; or R.sub.7 is ##STR4## wherein t is 0 or 1; or R.sub.5 and R.sub.9 taken together form a pyrrolidine ring and R.sub.6 and R.sub.8 are hydrogen and R.sub.7 is as described above; or R.sub.5 and R.sub.9 taken together form a pyrrolidine ring and then R.sub.6 is hydrogen and R.sub.7 and R.sub.8 taken together may form a phenyl, substituted phenyl, thienyl or furyl ring; or R.sub.5 and R.sub.8 taken together form a pyrrolidine ring and then R.sub.9 and R.sub.6 are hydrogen and R.sub.7 is phenyl, substituted phenyl, thienyl, or furyl; or R.sub.7 and R.sub.9 are hydrogen and R.sub.6 is benzyl, substituted benzyl, thienylmethyl, or furylmethyl; or a pharmaceutically acceptable salt thereof.

1-aminomethyl-1,2,3,4-tetrahydronaphthalenes

The present invention provides compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sub.1 is selected from hydrogen, halo, lower alkyl, lower alkoxy, or thioalkoxy; and R.sub.2 is lower alkoxy; or R.sub.1 and R.sub.2 together form a methylenedioxy or ethylenedioxy ring; R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, (lower alkyl)amino, (lower alkylsulfonyl)amino, and halo; and R.sub.7 is selected from the group consisting of 2- or 3-thienyl, 2- or 3-furyl, and ##STR2## where R.sub.13 and R.sub.14 are independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, lower alkyl, lower alkoxy, lower alkylthio, methylenedioxy, or ethylenedioxy. The compounds of the present invention selectively inhibit .alpha..sub.2 -adrenergic receptors as well as inhibit the uptake of biogenic amines and are thus useful in the treatment of certain cardiovascular and psychiatric disorders.

Compounds of the formula ##STR1## and pharmaceutically acceptable salt thereof, wherein R.sup.2 is selected from hydroxy and lower alkoxy, R.sup.5 is lower alkyl, and R.sup.11 and R.sup.12 are independently selected from hydrogen, halo, hydroxy, methoxy, and lower alkyl, are selective .alpha..sub.2 adrenergic receptor antagonists useful in the treatment of glaucoma.

Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.

Dopamine agonists

Growing community of inventors

Lake Forest, IL, United States of America

Fatima Z Basha